The 18 most recent market catalysts affecting $OCUL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 75
Oculis Announces FDA IND Clearance for Privosegtor in Acute Multiple Sclerosis Relapses
Oculis Holding AG announced FDA IND clearance for Privosegtor, enabling clinical development for acute multiple sclerosis relapses. This is a crucial regulatory milestone, as it al…
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 60
Oculis Management Provides Pipeline Update at Guggenheim Healthcare Innovation Conference
Oculis (OCUL) management presented a clinical pipeline update at the Guggenheim Healthcare Innovation Conference. The key takeaways include expected results for the PREDICT-1 study…
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 75
Ocular Therapeutix Reports Third Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix (OCUL) released its Q3 2026 financial results, which is a routine disclosure. The key takeaways, however, are the confirmation of a planned Q4 NDA submission for…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy Rating on Oculis Holding, Lowers Price Target
Guggenheim maintained its 'Buy' rating on Oculis Holding AG, indicating continued confidence in the company's long-term prospects. However, the simultaneous reduction of the price …
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 65
Oculis Holding AG Reports Third Quarter 2026 Financial Results
Oculis Holding AG's 8-K filing discloses its third-quarter 2026 financial results, showing a healthy cash position of CHF 210.3 million. The primary focus, however, is on the signi…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
Oculis Appoints Former Roche Executive Björn Tackenberg as Chief Scientific Officer
Oculis announced the appointment of Dr. Björn Tackenberg as its Chief Scientific Officer. This is a significant hire for Oculis as Dr. Tackenberg brings extensive experience from R…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 55
Oculis Appoints Björn Tackenberg as Chief Scientific Officer
Oculis Holding AG announced the appointment of Björn Tackenberg as Chief Scientific Officer, a key leadership role overseeing the company's scientific strategy and research portfol…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 65
Oculis Announces Upcoming Presentations on Privosegtor and PIONEER Program
Oculis Holding AG is providing updates on its clinical candidate, Privosegtor, which is being developed for optic neuropathies and acute multiple sclerosis relapses. The announceme…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 75
Oculis Reports New Phase 2 ACUITY Biomarker Data for Privosegtor
Oculis reported new biomarker data from its Phase 2 ACUITY study for Privosegtor, a small molecule peptide mimetic. The data is significant because it demonstrates Privosegtor's ab…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
UBS Maintains 75% Success Probability for Ocular Therapeutix's Axpaxli in Wet AMD
UBS analysts maintained a 75% success probability for Ocular Therapeutix's Axpaxli, a drug for wet AMD. This positive outlook comes despite the recent failure of EyePoint Pharmaceu…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 75
Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant
Oculis has fully randomized its first genotype-guided registrational trial for Licaminlimab, a precision medicine for dry eye disease. This is a crucial step in the drug developmen…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 65
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14
UBS analyst Alice Nettleton has initiated coverage on Ocular Therapeutix (OCUL) with a 'Buy' rating and a $14 price target. This is a positive development for Ocular Therapeutix as…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration
Ocular Therapeutix announced the successful completion of its Pre-NDA meeting with the FDA for AXPAXLI, an investigational product for wet age-related macular degeneration. This me…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Oculis Doses First PIONEER-1 Patient As Privosegtor Advances Into Registrational Testing For Optic Neuritis With FDA SPA Agreement
The dosing of the first patient in PIONEER-1 marks a critical milestone for Oculis, moving Privosegtor closer to potential market approval. The FDA's Special Protocol Assessment (S…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Ocular Therapeutix Stock Gaining Monday?
EyePoint Inc. (EYPT) announced underwhelming topline results from its pivotal Phase 3 LUGANO trial for Duravyu, a wet AMD treatment, failing to meet its primary visual acuity endpo…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares
Oculis is acquiring Privosegtor and ACT-02 assets from Accure, a move that significantly enhances its strategic position by gaining full ownership of a neuroprotective drug candida…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate
Ocular Therapeutix (OCUL) announced Q2 earnings per share of $(0.35), beating the analyst consensus of $(0.40), and sales of $13.475 million, surpassing the $13.199 million estimat…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 65
Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis Data
Oculis received positive pre-IND guidance from the FDA for Privosegtor in acute MS relapses, confirming that existing data can be leveraged for a new IND application planned for Q4…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.